戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tions during the first application of equine antivenom.
2  a necessary step in creating broad-spectrum antivenom.
3 ring medical attention and administration of antivenom.
4 velopment of effective humanized recombinant antivenom.
5 requiring medical intervention and sometimes antivenom.
6 or delayed hypersensitivity reactions to the antivenom.
7  development of safe and effective synthetic antivenom.
8  challenge to the development of a universal antivenom.
9 as a lead for the development of alternative antivenoms.
10 tential route to simple, synthetic, low-cost antivenoms.
11 e associated with hypersensitivity to equine antivenoms.
12  epitopes were detected by immunoblotting on antivenoms.
13 expanding access to funding for research and antivenoms.
14 , demands a radical redesign of many current antivenoms.
15 e, which is ineffectively treated by current antivenoms.
16 juries and is largely untreatable by current antivenoms.
17 d inspire strategies for design of new snake antivenoms.
18                                              Antivenom administration is the sole therapy against ven
19                    To assess the efficacy of antivenoms against dermonecrosis, a preclinical testing
20  target of IgE-mediated reactivity to equine antivenom and a possible cause of the high incidence of
21 enom would facilitate the production of both antivenom and novel therapeutics.
22  better than a currently used plasma-derived antivenom and therefore shows considerable promise for c
23     There is a severe shortage of affordable antivenoms and antitoxins in the developing world.
24                                         Both antivenoms and cetuximab induced positive skin prick tes
25  By detection of binding for three different antivenoms and performing an alanine scan, linear elemen
26 nderstand the molecular interactions between antivenom antibodies and epitopes on snake venom toxins,
27 eratively recovered two broadly neutralizing antivenom antibodies from the memory B cells of a hyperi
28                         A strong tendency of antivenom antibodies recognizing and binding to epitopes
29                                      Current antivenoms are antibody preparations obtained from the p
30                                  Traditional antivenoms are expensive, can cause adverse immunologica
31                                              Antivenoms are mammalian immunoglobulins with the abilit
32  the efficacy of scorpion-specific F(ab')(2) antivenom, as compared with placebo, was assessed in 15
33 ssess advantages over current plasma-derived antivenoms by offering superior safety and high neutrali
34 e aimed to develop an equivalent recombinant antivenom composed of a few neutralizing single chain an
35  and ImmunoCAP inhibition indicated that the antivenoms contained lower alpha-gal contents than cetux
36                           A new Fab fragment antivenom (CroFab) for the treatment of crotaline enveno
37 s sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole trea
38                         Currently, available antivenoms do not bind with strong specificity to target
39                                         This antivenom effectively prevented venom-induced lethality
40  has been shown to be a safe and efficacious antivenom for use in children as well as adults.
41 gency therapy still relies on antibody-based antivenom, hampered by poor access, frequent adverse rea
42            However, only a low proportion of antivenom immunoglobulins are specific to venom toxins,
43 tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE
44 y rendering the specific antibodies found in antivenoms ineffective against heterologous toxins found
45 ts confirmed that IgE-mediated reactivity to antivenom is associated with alpha-gal.
46                                              Antivenom is currently the first-choice treatment for sn
47                        Moreover, the cost of antivenom is expensive.
48 venoming, the production and clinical use of antivenom must be improved.
49       The polyclonal character of commercial antivenoms, obtained through the immunization of animals
50                Immediate hypersensitivity to antivenoms often occurs during the first administration
51                              The recombinant antivenom performed better than a currently used plasma-
52                                              Antivenoms, pork kidney, and cetuximab activated basophi
53 These findings will be valuable not only for antivenom production but also for the development of nov
54 ty of using pooled venoms as a substrate for antivenom production.
55 generation of skeletal muscle), although the antivenom (raised against the Indian 'Big Four' snakes)
56 stered in the placebo recipients than in the antivenom recipients (mean cumulative dose, 4.61 vs. 0.0
57 oncentrations were undetectable in all eight antivenom recipients but in only one placebo recipient 1
58 , with a resolution of symptoms in all eight antivenom recipients versus one of seven placebo recipie
59 , hyperimmune equine or ovine plasma-derived antivenoms remain the only specific treatment for snakeb
60 dministration of scorpion-specific F(ab')(2) antivenom resolved the clinical syndrome within 4 hours,
61 esolved more rapidly among recipients of the antivenom than among recipients of placebo, with a resol
62 ions is fundamental for producing a specific antivenom that has high effectiveness, low side effects,
63 ng in an experimental polyvalent recombinant antivenom that was capable of neutralizing seven toxin f
64 es on outdated and poorly tolerated biologic antivenoms that are often weakly efficacious, must be gi
65 ective and widely accessible next-generation antivenom therapeutics.
66 juvant treatments to complement conventional antivenom therapy based on inhibitory molecules for spec
67 ion of a monoclonal antibody-based universal antivenom to treat snakebite envenoming.
68 on group received LLLT combined with regular antivenom treatment.
69 in venom composition dictates that different antivenom treatments are used in different parts of the
70 rong protective power of small quantities of antivenom used in the context of severe envenomation wit
71                     The effectiveness of the antivenom was tested in vivo under conditions simulating
72 decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two
73                                              Antivenoms were screened for alpha-gal epitopes via immu
74 ent standard of care involves antibody-based antivenoms, which can be difficult to access and are gen
75 othesized that a scorpion-specific F(ab')(2) antivenom would promptly resolve clinical symptoms in ch